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Abstract
Background: Cardiovascular phosphorus MR spectroscopy (31P-CMRS) is a powerful tool for probing energetics in
the human heart, through quantification of phosphocreatine (PCr) to adenosine triphosphate (ATP) ratio. In principle,
31P-CMRS can also measure cardiac intracellular pH (pHi) and the free energy of ATP hydrolysis (ΔGATP). However, these
require determination of the inorganic phosphate (Pi) signal frequency and amplitude that are currently not robustly
accessible because blood signals often obscure the Pi resonance.
Typical cardiac 31P-CMRS protocols use low (e.g. 30°) flip-angles and short repetition time (TR) to maximise signal-to-
noise ratio (SNR) within hardware limits. Unfortunately, this causes saturation of Pi with negligible saturation of the
flowing blood pool. We aimed to show that an adiabatic 90° excitation, long-TR, 7T 31P-CMRS protocol will
reverse this balance, allowing robust cardiac pHi measurements in healthy subjects and patients with hypertrophic
cardiomyopathy (HCM).
Methods: The cardiac Pi T1 was first measured by the dual TR technique in seven healthy subjects. Next, ten healthy
subjects and three HCM patients were scanned with 7T 31P-MRS using long (6 s) TR protocol and adiabatic excitation.
Spectra were fitted for cardiac metabolites including Pi.
Results: The measured Pi T1 was 5.0 ± 0.3 s in myocardium and 6.4 ± 0.6 s in skeletal muscle. Myocardial pH was 7.12 ±
0.04 and Pi/PCr ratio was 0.11 ± 0.02. The coefficients of repeatability were 0.052 for pH and 0.027 for Pi/PCr quantification.
The pH in HCM patients did not differ (p= 0.508) from volunteers. However, Pi/PCr was higher (0.24 ± 0.09 vs. 0.11 ± 0.02;
p= 0.001); Pi/ATP was higher (0.44 ± 0.14 vs. 0.24 ± 0.05; p= 0.002); and PCr/ATP was lower (1.78 ± 0.07 vs. 2.10 ± 0.20; p= 0.
020), in HCM patients, which is in agreement with previous reports.
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Conclusion: A 7T 31P-CMRS protocol with adiabatic 90° excitation and long (6 s) TR gives sufficient SNR for Pi and low
enough blood signal to permit robust quantification of cardiac Pi and hence pHi. Pi was detectable in every subject
scanned for this study, both in healthy subjects and HCM patients. Cardiac pHi was unchanged in HCM patients,
but both Pi/PCr and Pi/ATP increased that indicate an energetic impairment in HCM. This work provides a robust
technique to quantify cardiac Pi and pHi.
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Background
Phosphorus cardiovascular magnetic resonance spectros-
copy (31P-CMRS) is a valuable technique for non-inva-
sive measurement of high-energy metabolites, e.g.
adenosine triphosphate (ATP) and phosphocreatine
(PCr), that allows assessment of tissue energy metabol-
ism in vivo [1, 2]. The cardiac PCr/ATP ratio has been
established as a biomarker that changes in most major
cardiac disease states [3–5], and which predicts mortality
in patients with dilated cardiomyopathy [3]. Decreased
cardiac PCr/ATP ratios are also observed in obesity [6]
and type-II diabetes [7], revealing cardiac involvement in
these systemic diseases.
In principle, 31P-CMRS can also be used to measure
cardiac intracellular pH (pHi) and the free energy change
of ATP hydrolysis (ΔGATP). However, these require ac-
curate determination of the inorganic phosphate (Pi) sig-
nal frequency and amplitude. These are currently not
robustly accessible because signals from 2,3-diphospho-
glycerate (2,3-DPG) in the ventricular blood pools often
obscure the signal from Pi in the myocardium.
Several groups reported pHi and the Pi/PCr ratio mea-
sured in patients with hypertrophic cardiomyopathy
(HCM) by 1H-decoupled 31P-CMRS at 1.5 T in the
1990s [8, 9]. In healthy subjects, the detection of cardiac
Pi using 1H-decoupling was not possible in all subjects,
primarily due to the small concentration of Pi in the
heart and the inherently low signal-to-noise ratio (SNR)
of 31P-CMRS at 1.5T [9]. Scanning at ultra-high field
(7T) increases the SNR of cardiac 31P-CMRS substantially
[10]. Additionally, it also enhances the spectral separation
between signals from different metabolites. This may enable
detection of cardiac Pi without 1H-decoupling, which is in-
feasible at 7T due to limits on specific absorption rate
(SAR). However, typical 31P cardiac spectra are acquired
using short TR of about 1 s, and low flip-angle to maximize
the SNR/time [10]. Based on skeletal muscle data [11], it
can be expected that cardiac Pi will have relatively long re-
laxation time T1 (several seconds), and thus, experience
strong partial saturation. At the same time, the majority of
blood in the ventricles is replenished at each heartbeat, so
the undesired 2,3-DPG signal is undiminished when scan-
ning with a surface radiofrequency (RF) coil, as is the case
in almost all cardiac 31P-CMRS studies [12].
Furthermore, it is essential to know the excitation
flip-angle for quantification of metabolite ratios, e.g., Pi/
PCr. Regrettably, surface RF coils have a transmit field
(B1
+) that drops off rapidly with distance from the coil.
This makes metabolite quantification difficult, especially
at ultra-high fields. We recently demonstrated feasibility
of excitation with a B1
+-insensitive 90° adiabatic pulse
for cardiac 31P-CMRS at 7T, which simplifies the quanti-
fication of metabolite ratios [13].
The aim of this work was to test the performance and
robustness of a cardiac 7T 31P-CMRS protocol with a
relatively long TR = 6 s and 90° adiabatic excitation for
quantification of cardiac intracellular pH (pHi) and Pi/
PCr ratio in the human heart. To this end, we also mea-
sured the T1 relaxation time of cardiac Pi using the dual
TR technique [14] in seven healthy subjects; performed
test-retest reproducibility of intracellular pH calculation
in eight healthy subjects; and demonstrated our ap-
proach in three patients with HCM.
Methods
All measurements were performed on a 7T whole body,
research-only MR system (Siemens Healthineers, Erlangen,
Germany) equipped with a custom-built dual-tuned (31P/1H)
surface RF-coil, comprising a quadrature 31P coil (two 15 cm
loops, with overlap decoupling) and a single 1H loop (10 cm
in diameter) for localization (Fig. 1) [15]. The coil was posi-
tioned over the heart of participants lying supine. No cardiac
gating or respiratory triggering were used [10].
In vivo experiments
In total, 12 healthy subjects (27 ± 5 years; 3 females) and
three HCM patients were recruited in compliance with
local regulations and institutional ethics committee after
giving informed consent. The in vivo experiments can
be divided into three main groups: (a) direct comparison
of short TR and long TR acquisition, using an amplitude
modulated excitation pulse, or a B1
+ insensitive adiabatic
half-passage (AHP) pulse; (b) measurement of T1 of car-
diac Pi; and (c) quantification of cardiac Pi/PCr and pHi
in healthy subjects and HCM patients. Some of the sub-
jects took part in several of the in vivo experiments.
The feasibility to detect cardiac Pi using long vs short
TR was first tested in one healthy subject by using two
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consecutive 3D ultrashort echo time (UTE) chemical
shift imaging (CSI) [16] acquisitions. The first had a
“short” (1 s) TR, and the other a “long” (5 s) TR. Both
had matrix size (8 × 16 × 8), field of view (FOV) (240 ×
240 × 200 mm3) and used acquisition weighting. This
translates into an effective voxel size of 50.7mL [13].
The number of averages (NA) was matched for equal ac-
quisition time, giving 41 averages for the short and 5 aver-
ages for the long TR measurement. An amplitude-modulated
excitation pulse (1 ms long) applied in previous 7T
studies was used [10].
Next, the recently proposed AHP pulse [13] was ap-
plied in three volunteers. In order to use this relatively
SAR demanding pulse (7.5 ms long) with short TR (1 s),
the 3D UTE-CSI [16] sequence was modified to allow an
interleaved TR acquisition with two different TRs [17].
In this case, the second TR was matched to the effective
TR in the AHP study, i.e. 6 s TR [13]. Matrix size and
FOV matched the first experiment and acquisition
weighting with 5 averages at the centre of k space was
used for both TRs. The excitation frequency of the AHP
pulse was centred at the 2,3-DPG signal, i.e. + 700 Hz
relative to PCr.
Seven subjects were consecutively scanned using the
dual TR technique [14] for determination of the T1 of
cardiac Pi, which is required for quantification of the de-
tected myocardial Pi. Since the interleaved TR acquisi-
tion is not suitable for T1 determination [17], two
successive 3D UTE-CSI [16] acquisitions were required.
The SAR limits for the narrow-banded AHP pulse [13]
we used allowed for a 3 s minimum TR. Our chosen TR
values were therefore: TR1 = 3 s and TR2 = 6 s. The
matrix size and FOV again matched the original proto-
col, i.e. 8 × 16 × 8 and 240 × 240 × 200 mm3, respectively.
The AHP pulse we used has a relatively narrow
bandwidth for typical B1
+ in the heart for our coil. So,
the excitation was centred at + 600 Hz from PCr and the
smooth side of the pulse’s frequency profile was facing
towards PCr. Numerical solutions of the Bloch Equa-
tions were performed in Matlab (MathWorks, Natick,
Massachusetts, USA) to estimate the potential errors in
calculated T1 for resonance offsets from − 180 Hz to +
180 Hz from centre frequency, for the T1 values from 1 s
to 10 s (Fig. 2).
Ten healthy subjects then underwent cardiac 7T
31P-CMRS examinations for cardiac pH, Pi/PCr and Pi/
ATP quantification using interleaved AHP excitation
[13]. In short, the AHP excitation was interleaved to ex-
cite the PCr and ATP region in odd acquisitions and the
Pi and DPG region in even acquisitions. The effective
TR was 6 s and other parameters matched the T1 mea-
surements. The total acquisition time was 46 min and
42 s. In a subset of these subjects (n = 8), the measure-
ment was performed twice to assess the repeatability of
cardiac pHi and Pi/PCr determination.
Finally, to demonstrate the feasibility of the technique
in patients, three male patients with established diagno-
ses of HCM (57 ± 12 years, mean wall thickness 21 ± 2
mm) were recruited and scanned with the interleaved
AHP protocol [13] to determine their cardiac pH, Pi/
PCr and Pi/ATP. The acquisition time for patients was
the same as for healthy subjects, i.e. 46 min and 42 s.
Data analysis
For each subject, three septal voxels in the two mid left
ventricular slices (six in total) were selected for further
analysis. In addition, six chest muscle voxels were also
selected for the T1 analysis. Spectra from all selected
voxels were fitted using the OXSA toolbox [18] and its
implementation of the AMARES time-domain fitting
Fig. 1 A photograph of our custom-built dual-tuned (31P/1H) surface RF-coil, comprising a quadrature 31P coil (two 15 cm loops, with overlap decoupling)
and a single 1H loop (10 cm in diameter) described in detail in Schaller et al. [15]
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algorithm [19]. The PCr signal, fitted as single Lorentzian,
and the γ-ATP signal, fitted as a Lorentzian doublet, were
quantified from the odd acquisition spectra. The Pi and
2,3-DPG signals, all fitted as single Lorentzians, were
quantified from the even acquisition spectra. The reson-
ance frequency of Pi was constrained to the 4.7–5.1 ppm
range and the two 2,3-DPG peaks were constrained to
5.2–5.7 ppm and 6.0–6.3 ppm, respectively. The same
constraints for linewidth, i.e. 20-60Hz, without dependen-
cies on other peaks were applied for both 2,3-DPG signals
and for Pi signal. If a limit was reached during fitting, fit-
ting was repeated with the constraints extended by ±5Hz.
The T1 relaxation of Pi was determined in cardiac and
skeletal muscle voxels using the dual TR technique [14].
ATP and Pi signals were corrected for blood contamin-
ation as previously described [20]. Cramér-Rao lower
bounds (CRLB) [21] were determined for the Pi peak
amplitudes and voxels with the CRLB ≥15% were ex-
cluded. Remaining cardiac data were further corrected
for partial saturation effects using the calculated T1
values for Pi and literature T1 values for γ-ATP and PCr
[10]. As our voxels are relatively big, to confirm that the
quantification of Pi did not depend on how much blood
contamination was in the voxel, we have performed a
correlation analysis between our reported blood-cor-
rected Pi/PCr values and the 2,3-DPG/PCr ratio using
all evaluated voxels, i.e. including the repeatability data.
The cardiac intracellular pHi was calculated from the
chemical shift between Pi and PCr using the modified
Henderson-Haselbach equation [22]. The Pi/PCr ratio
and pHi were compared between the two repeated
measurements of healthy subjects by Bland-Altman ana-
lysis of agreement [23]. Coefficients of repeatability were
estimated as 1.96 × √2 × intra-subject standard deviation
(SD) [24]. Data are presented as mean ± SD. Student’s
t-test was used to compare the PCr/ATP, Pi/ATP, Pi/PCr
and pHi of healthy subjects and HCM patients, with
p < 0.05 considered statistically significant.
Results
In the datasets acquired using the short TR, it was not
possible to distinguish a Pi peak in voxels of interven-
tricular septum, due to strong overlapping 2,3-DPG sig-
nals from blood. Although similarly strong 2,3-DPG
signals were observed in the data acquired with long TR,
the long TR acquisition allowed clear visibility of the Pi
peak above 2,3-DPG in these voxels (Fig. 3).
Our Bloch simulations showed that the error in T1 es-
timation, using the dual TR technique and selected TRs
of 3 s and 6 s, increases with increasing frequency offset
(Fig. 2). There is a steeper rise in T1 error on the sharper
side of the AHP pulse frequency profile. Nevertheless,
T1 errors < 20% are predicted for frequency offsets be-
tween − 30 Hz and + 35 Hz throughout the simulated T1
range (1–10 s). Representative spectra from skeletal
muscle and interventricular septum are depicted in Fig. 4.
The mean measured T1 relaxation time of Pi was 6.4 ±
0.6 s in chest muscle tissue and 5.0 ± 0.3 s in interven-
tricular septum.
In total, 108 septal voxels were analysed for pH and Pi
quantification in healthy subjects, i.e. 6 voxels per meas-
urement (n = 18, including the scan-rescan data). Out of
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Fig. 2 Simulations of the Bloch Equations for potential off-resonance errors in T1 measured using the dual TR technique with AHP excitation, at
the lowest B1
+ expected in vivo at the depth of the heart, i.e. ~ 10 cm from the coil. The simulations were performed for resonance offsets ranging
from − 180 Hz to 180 Hz from the centre frequency and for the T1 values ranging from 1 s to 10 s. The 20% error margin for T1 estimation is depicted
as a grey dashed line
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these, 93 voxels had CRLB of Pi < 15%, with the mean
CRLB of 10.6 ± 1.8%. On average, 5.2 ± 1.0 voxels per
dataset were analysed further, with at least 4 voxels used
in 17 datasets and 2 voxels in one. Figure 5 depicts a
representative fit of a cardiac voxel acquired during the
even acquisition.
Table 1 denotes the calculated metabolite ratios and
cardiac pHi for each subject. The mean myocardial pH
of healthy subjects was 7.12 ± 0.04 and the Pi/PCr ratio
was 0.11 ± 0.02. Figure 6 depicts the Bland-Altman plots
of the in vivo test-retest measurements of myocardial
pH and Pi/PCr. The mean absolute biases given by the
analysis of agreement were only 0.007 and 0.003, with
the limits of agreement of ±0.069 and ± 0.036 for pH
and Pi/PCr, respectively. The estimated repeatability co-
efficients were 0.052 and 0.027 for pH and Pi/PCr, re-
spectively. No correlation was found between the
blood-corrected Pi/PCr and 2,3-DPG/PCr values in this
study (r = 0.001, p = 0.992).
Figure 7 shows representative septal spectra acquired
in a healthy subject and an HCM patient. More domin-
ant cardiac Pi signal can be seen in the patient’s
spectrum. A lower PCr/ATP ratio (1.78 ± 0.07 vs. 2.10 ±
0.20; p = 0.020) and higher Pi/ATP (0.44 ± 0.14 vs. 0.24 ±
0.05; p = 0.002) and Pi/PCr (0.24 ± 0.09 vs. 0.11 ± 0.02;
p = 0.001) ratios were found in HCM patients com-
pared to young healthy subjects. Detailed information
is given in Table 1.
Discussion
We proposed using 7T 31P-CMRS with adiabatic excita-
tion and long TRs to quantify cardiac Pi and determine
pHi in vivo. Our results show that this approach allows
robust detection of cardiac Pi in healthy subjects and
also patients with HCM. The direct detection of cardiac
Pi makes cardiac pHi determination straightforward. We
demonstrated excellent repeatability of this method, with
limits of agreement: ±0.069 and ± 0.036 for pH and Pi/
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Fig. 3 Spectra acquired with the interleaved TR sequence using a single AHP excitation frequency centred at the 2,3-DPG resonance (marked
with a black arrow near the x-axis in the red voxel spectra). Spectra are shown for voxels in the chest wall muscle down to the intraventricular
septum. Note the increased Pi amplitude in all voxels acquired at longer TR, demonstrating the improved detectability of Pi, which allows for
reliable cardiac pHi determination. The effective voxel size is depicted using a dashed white line
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PCr, respectively. We also measured the T1 for myocar-
dial Pi at 7T, which permits quantification of cardiac Pi/
PCr.
Our protocol using long TR acquisition and adiabatic
90° excitation at 7T allowed for detection of myocardial
Pi in vivo. In typical cardiac 31P-CMRS experiments, Pi
is obscured by a dominant overlapping signal from
2,3-DPG in the blood pool. This approach is successful
because the long TR reduces the effect of partial T1 sat-
uration on Pi, which in typical short TR acquisitions
strongly reduces the myocardial tissue signal leaving the
2,3-DPG signal from in-flowing blood almost intact. We
demonstrated the effect of TR on Pi detection by com-
paring long and short TR acquisitions in the same
subjects.
The majority of previously published studies quantify-
ing cardiac pHi by
31P-CMRS used 1H-decoupling to re-
duce the 2,3-DPG linewidth and minimise overlap with
Pi [8, 9]. Although, 1H-decoupled 1.5 T 31P-CMRS was
shown to be effective in HCM patients, its feasibility in
healthy subjects was limited, e.g. de Roos et al. reported
a 44% success rate (n = 4/9) in healthy subjects [9]. Jung
et al. were able to reliably fit myocardial Pi in only 82%
(n = 9/11) of cases [8]. In 100% of our healthy subject
(n = 18/18), it was possible to find at least two septal
voxels where AMARES fitted the Pi peak reliably (i.e.
with CRLB < 15%), and in 94% cases we were able to
fit Pi robustly in at least four out of our six targeted
voxels. The improved SNR from scanning at 7T
makes our approach robust. In future, we envisage
that optimised per-subject B0 shimming would further
aid separation of Pi and 2,3-DPG signals in our ap-
proach [25]. An alternative technique for determining
cardiac pHi was introduced by Blamire et al., who re-
corded spectra with and without saturation of the
γ-ATP resonance. Subtracting these spectra sup-
presses 2,3-DPG and leaves signal from Pi generated
by ATP hydrolysis [26]. They also achieved a 100%
success rate (n = 6/6) for cardiac pHi determination
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Fig. 4 31P-CMRS spectra acquired in the chest muscle (blue voxel - upper row) and human heart (green voxel - bottom row) with TR1 = 3 s (left)
and TR2 = 6 s (right). Spectra were acquired with a single AHP excitation frequency centred on Pi (marked with a black arrow near the x-axis). Please
note that while spectra are scaled equally for TR1 and TR2, the heart spectra are scaled differently than the skeletal muscle spectra. A 30 Hz Lorentzian
filter was applied to all spectra for better visualization. A pronounced Pi signal can be seen in TR2 spectra both in chest muscle and in the heart. Due
to the limited excitation bandwidth of the AHP pulse, β-ATP peak is not excited, and thus, not shown
























Fig. 5 A representative result of the fitting procedure. A mid-septal spectrum measured during an even acquisition overlaid by the final spectral
fit (top); individual peaks fitting (middle) and the residual (bottom) is depicted
Table 1 Calculated metabolite ratios and cardiac pHi for every volunteer and patient
Participant PCr/ATP Pi/ATP Pi/PCr pH
Meas.1 Meas.2 Meas.1 Meas.2 Meas.1 Meas.2 Meas.1 Meas.2
Healthy subject #1 1.79 ± 0.39 1.86 ± 0.51 0.22 ± 0.19 0.24 ± 0.17 0.12 ± 0.10 0.13 ± 0.09 7.10 ± 0.13 7.10 ± 0.06
Healthy subject #2 2.15 ± 0.68 2.28 ± 1.09 0.25 ± 0.14 0.17 ± 0.10 0.11 ± 0.03 0.08 ± 0.04 7.08 ± 0.15 7.07 ± 0.07
Healthy subject #3 1.82 ± 0.38 2.04 ± 0.44 0.24 ± 0.08 0.29 ± 0.09 0.14 ± 0.07 0.14 ± 0.05 7.17 ± 0.28 7.15 ± 0.08
Healthy subject #4 2.25 ± 0.63 2.17 ± 0.63 0.24 ± 0.10 0.22 ± 0.12 0.11 ± 0.04 0.10 ± 0.07 7.16 ± 0.11 7.17 ± 0.04
Healthy subject #5 2.32 ± 0.47 2.37 ± 0.58 0.19 ± 0.10 0.23 ± 0.16 0.08 ± 0.04 0.12 ± 0.11 7.11 ± 0.05 7.11 ± 0.02
Healthy subject #6 2.08 ± 0.41 1.84 ± 0.45 0.17 ± 0.10 0.22 ± 0.05 0.08 ± 0.06 0.09 ± 0.03 7.09 ± 0.05 7.15 ± 0.02
Healthy subject #7 2.14 ± 0.62 2.10 ± 0.68 0.22 ± 0.22 0.23 ± 0.15 0.11 ± 0.12 0.11 ± 0.09 7.13 ± 0.03 7.08 ± 0.02
Healthy subject #8 2.19 ± 0.19 2.37 ± 0.43 0.27 ± 0.12 0.26 ± 0.12 0.12 ± 0.05 0.11 ± 0.05 7.17 ± 0.01 7.12 ± 0.02
Healthy subject #9 2.36 ± 0.53 N/A 0.35 ± 0.24 N/A 0.14 ± 0.10 N/A 7.10 ± 0.05 N/A
Healthy subject #10 1.93 ± 0.57 N/A 0.24 ± 0.11 N/A 0.13 ± 0.06 N/A 7.14 ± 0.06 N/A
Mean 2.10 ± 0.20 2.13 ± 0.21 0.24 ± 0.05 0.23 ± 0.04 0.11 ± 0.02 0.11 ± 0.02 7.12 ± 0.04 7.12 ± 0.04
HCM #1 1.75 ± 0.45 0.48 ± 0.28 0.26 ± 0.12 7.16 ± 0.03
HCM #2 1.73 ± 0.67 0.56 ± 0.32 0.32 ± 0.16 7.12 ± 0.04
HCM #3 1.86 ± 0.33 0.28 ± 0.14 0.14 ± 0.05 7.14 ± 0.07
Mean 1.78 ± 0.07* 0.44 ± 0.14* 0.24 ± 0.09* 7.14 ± 0.02
% change −15 + 83 + 118 0.21
Data are given as inter-voxel mean ± SD and the mean data are given as inter-subject mean ± SD, *denotes significant difference (p < 0.05) between healthy
subjects and HCM patients
Values from both measurements of the repeatability study are given
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A) B)
Fig. 6 Bland-Altman plots of the in vivo test-retest quantification of pH (a) and Pi/PCr ratio (b) in the human heart septum using long TR 31P-CMRS
with adiabatic excitation at 7 T. The mean absolute differences between the two scans were 0.007 for pH and 0.003 for Pi/PCr, showing very low bias.
















Fig. 7 Representative mid-septal spectra with corresponding localizers acquired in a healthy subject (a, c) and an HCM patient (b, d). The spectra
shown are a combination of the two interleaved AHP frequency data sets: one acquired with the excitation centred between PCr and γ-ATP
(black) and the other with the excitation centred between the 2,3-DPG resonances (grey). The excitation frequencies are marked with arrows of
corresponding colour near the x-axis. Spectra are scaled equally for the healthy subject and the HCM patient. Please note the more dominant
cardiac Pi signal and ATP signals in the patient’s spectrum and the reduced 2,3-DPG reflecting that more of the voxel is filled with myocardium
due to LV wall thickening
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for direct Pi/PCr quantification because Pi is visible
only in the difference spectrum [26].
We have measured the T1 of Pi in myocardial septum
as well as in skeletal muscle, to allow quantification of
Pi. This was possible using the dual TR technique [14].
Although the shortest possible TR was limited by SAR,
our simulations show that our TRs would have < 20%
error in T1. The method can tolerate 0.5 ppm
mis-adjustment of the 31P transmitter frequency. The
mean T1 value we measured in the chest muscle (6.4 ±
0.6 s) is in good agreement with literature [10, 11]. Our
mean measured T1 value for cardiac Pi (5.0 ± 0.3 s) was
shorter than the literature values measured in the calf
muscle at 7T (6.3 ± 1.0 s [11] and 6.7 ± 0.2 s [10]). This is
in agreement with shorter T1 times of PCr and ATP re-
ported in the heart in comparison to skeletal muscle
[10]. Our T1 of Pi measured in human heart is also
in good accordance with the value reported for 2 T
(4.3 ± 2.4 s) [27] given that T1 values change with field
strength [11].
We found no significant difference in cardiac pHi be-
tween healthy subjects and HCM patients (7.12 ± 0.04 vs
7.14 ± 0.02; p = 0.508). Even though our patient sample is
rather small, this agrees with previous reports [8, 9, 28].
Our measured cardiac pHi agrees with literature values
showing mean cardiac pHi ranging from 7.06 to 7.15 for
healthy subjects [8, 9, 26, 28, 29]. Furthermore, our repeat-
ability test showed good agreement between the cardiac
pHi measured in the two acquisitions, with the limits of
agreement being 0.007 ± 0.069 and the estimated repeat-
ability coefficient being 0.052. This is to our knowledge
the first published reproducibility for cardiac pHi meas-
urement published.
Previous studies have reported both a reduced PCr/
ATP and an increased Pi/PCr in HCM patients com-
pared to healthy subjects [8, 9, 28, 30]. In line with these
findings, we have found a lower PCr/ATP ratio in HCM
patients (1.78 ± 0.07 vs. 2.10 ± 0.20; − 15%; p = 0.020).
Furthermore, Pi/PCr (0.24 ± 0.09 vs. 0.11 ± 0.02; 118%;
p = 0.001) and Pi/ATP (0.44 ± 0.14 vs. 0.24 ± 0.05; 83%;
p = 0.002) ratios were significantly higher in HCM
compared to controls. Comparing absolute numbers,
de Roos et al. [9] reported Pi/PCr ratios of 0.14 ± 0.06
and 0.20 ± 0.04 for healthy subjects and HCM pa-
tients, i.e. a 43% increase. Similarly, Jung et al. [8] re-
ported 0.10 ± 0.07 and 0.20 ± 0.08 Pi/PCr ratios in
healthy control subjects and HCM patients, i.e. an in-
crease of 100%. We observed a slightly larger (118%)
increase of Pi/PCr ratios in HCM patients, albeit in a
small cohort. Our Bland-Altman analysis of agreement
between repeated measurements of Pi/PCr ratio
showed limits of agreement of − 0.003 ± 0.036 and the
estimated repeatability coefficient was 0.027. It has
been proposed previously that increased Pi in the
heart may directly inhibit contractile function since
the release of Pi from the actin-myosin cross bridge
is associated with force development [31] and was
shown to correlate with the myocardial contractile
force at the onset of ischemia in animal studies [32].
It has been also suggested lately that the Pi is both
the primary feedback signal for stimulating oxidative
phosphorylation in vivo and also the most significant
product of ATP hydrolysis in limiting the capacity of
the heart to hydrolyse ATP in vivo [33]. The scope of
this technical work was limited, and thus at this time
we can neither confirm nor refute these previous
findings on the changes in Pi and pHi due to HCM.
However, this work paves the way for studies that will
be able to test these theories in more adequately
powered larger patient cohorts.
The main limitation of our study is the relatively long
acquisition time required (47 min) due to the combin-
ation of 3D-CSI localisation and long 6 s TR. However,
trying to shorten the scan time by reducing the TR
would limit the detectability of cardiac Pi, and it would
also likely exceed SAR restrictions because of the adia-
batic excitation pulses used [13]. Faster localization
strategies, e.g., 1D-image selected in vivo spectroscopy
(1D-ISIS) or 1D-CSI could potentially be combined with
our approach for cardiac Pi detection, but our RF-coil
has insufficient peak B1
+ for an effective inversion pulse
and too large a sensitive volume for effective localisation
of cardiac signal by 1D-ISIS or 1D-CSI [13]. Acquisition
of data with higher spatial resolution, i.e. smaller voxel
size, could also help to minimize the signal contamin-
ation from the blood pool, but this again requires com-
parably long acquisition time even with a short TR and
reduced number of averages, which could in turn limit
the detectability of cardiac Pi in healthy subjects [34].
Conclusion
In conclusion, we present a technique for reliable quanti-
tation of cardiac Pi and determination of cardiac intracel-
lular pH (pHi) using 7T
31P-CMRS with adiabatic
excitation and a long TR. We achieved 100% success rate
for Pi detection in the hearts of 10 consecutively recruited
healthy subjects and in three HCM patients. We were also
able to measure the longitudinal relaxation time of cardiac
Pi at 7T. This allowed for quantification of the cardiac Pi/
PCr and Pi/ATP ratios, which were significantly increased
in three patients with HCM. This new technique will
allow addressing an array of clinically relevant questions
related to the role of Pi in cardiac diseases.
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